LCTX
Lineage Cell Therapeutics, Inc.
LCTX
Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics NYSEAMERICAN: LCTX outlined progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease, Type
Lineage Cell Therapeutics, Inc. (LCTX) Q2 2026 Earnings Call Transcript
Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript